How Does CAR-T Therapy’s Efficacy Translate to Clinical Value for Hong Kong Patients with Refractory Hematological Malignancies, and How Can Optimized Manufacturing Help Close the Current Access Gap?. Journal of Medicine and Life Sciences, [S. l.], v. 2, n. 1, p. 53–70, 2026. DOI: 10.71222/dt007s28. Disponível em: https://www.gbspress.com/index.php/JMLS/article/view/636. Acesso em: 30 apr. 2026.